VIVUS, Inc.(NASDAQ:VVUS) shares opened lower by 1.26%
after soaring 3% in the previous trading session. Recently, stock has seen
selling pressure last after last Friday an analyst at an analyst at Jefferies slashed
his sales estimates for company’s new obesity drug Qsymia.
Vivus Inc.'s new obesity drug Qsymia could create
confusion among medical practitioners who may prescribe Qsymia's generic
versions rather than drug itself for their patients.
Analyst Thomas Wei who pointed out this scope for
error downgraded the firm's rating to Underperform from Hold and also slashed
the price target of the stock to $16 from $31 a share.
Shares in Vivus fell nearly 8 percent on Friday after
the downgrade and the concerns expressed by Wei.
Get Complete Analysis
on VVUS Here
Wei said that confusion could cut into the sales of
the drug and he estimated that sales of Qsymia would peak at $1.2 billion a
year compared to the earlier forecast of $3.6 billion.
The U.S. Food and Drug Administration had approved the
Qsymia on July 17, which was seen as more effective than two other anti-obesity
pills which had been approved earlier. Qsymia would start selling later this
year.
Qsymia is made of up two older drugs topiramate and
phentermine, which has lost patent protection.
Vivus argued that most doctors are more likely to
prescribe Qsymia instead of generic topiramate and phentermine because of
concerns about their legal liability. Also patients who take the generic drugs
may experience side effects and doctors would not like to take that risk.
However Wei said he was sceptical of the company's
reasoning. He added the generics will also be less expensive and a combination
of the two generic drugs appeared to be as effective as Qsymia in one clinical
trial.
No comments:
Post a Comment